References
- Longo D.T., Mauch P., DeVita V.T., Urba W.J., Jaffe E.S. Lymphocytic lymphoma. Cancer: Principles and practice of oncology4nd edn, V.T. De Vita, S. Hellman, S.A. Rosenberg. Lippincott, Philadelphia 1993; 1859–1927
- Hollingshead L.M., Faulds D. Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690–719
- Gillies H., Liang R., Rogers H., Harper P., Parapia L., Cox G., Johnson S. Phase II trial of idarubicin in patients with advanced lymphoma. Cancer Chemother. Pharmacol 1988; 21: 261–264
- Lopez M., Di Lauro L., Papaldo P. Oral idarubicin in non hodgkin's lymphoma. Invest. New. Drugs 1986; 4: 263–267
- Kantarjian H., Bartologie B., Plunkett W., Velasquez W., McLaughin P., Riggs S., Cabanillas F. High dose cy-tosine arabinoside in non Hodgkin's lymphoma. J. Clin. Oncol. 1983; 11: 689–694
- Soiffer R.J., Caligiuri M.A., Tondini C., Canellos P. High dose cytosine arabinoside in relapsed and refractory non hodgkin's lymphoma. Limited role as single agent. Cancer 1989; 64: 2014–2018
- Dufour P., Herbrecht R., Hurteloup P., Maloisel F., Duclos B., Bergerat J-P., Oberling F. Idarubicin and high dose cytosine arabinoside as salvage therapy for non Hodgkin lymphoma: feasibility study and preliminary results. ECCO 5, London 3–7 September, 1988, Abstract n° P-0392
- The International Non Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non Hodgkin's lymphoma. N Engl J Meet 1993; 329: 987–994
- Case D.C., Gerber M.C., Gams R.A., Crauwford J., Votaw M.L., Higano C.S., Pruitt B.T., Gould J. Phase II study of intravenous idarubicin in unfavorable non hodgkin's lymphoma. Cancer Res. 1992; 52: 3871–3874
- Case D.C., Hayes D.M., Gerber M., Gams R.A., Crawford J., Votaw M.L., Higano C.S., Pruitt B.T., Gould J. Phase II study of oral idarubicin in favorable histology non hodgkin's lymphoma. Cancer Res. 1990; 50: 6833–6835
- Coonley C.J., Warrell R.P., Strauss D.J., Young C.W. Clinical evaluation of 4 Demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treat. Rep. 1983; 67: 949–950
- Cabanillas F., Hagemeister F.B., Bodey G.P., Freireich E.J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
- Herbrecht R., Ortiz S., Damonte J.C., Liu K.L., Maloisel F., Dufour P., Bergerat J.-P., Oberling F. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non hodgkin's lymphoma after failure of the LNH 84 regimen. Hematol. Oncol 1991; 8: 253–257
- Velasquez W.S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F.B., Redman J.R., Swan F., Barlogie B. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
- Huijgens P.C., Ossenkoppele G.J., Vanderlevie J., Thomas L.M., Wijngaarden M.J., Slaper C.M. IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma. Hematol. Oncol 1991; 9: 245–261
- Kessinger A., Vose J., Bierman P.J., Armitage J.O. High dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. Exp. Hematol 1991; 19: 1013–1016
- Bosly A., Coiffier B., Gisselbrecht C., Tilly H., Auzanneau G., Andrien F., Herbrecht R., Legros M., Devaux Y., Jaubert J., Pignon B., Michaux J.L., Humblet Y., Dupriez B., Thyss A., Lederlin P. Bone marrow transplantation prolongs survival after relapse in agressive lymphoma patients treated with the LNH-84 regimen. J. Clin. Oncol 1992; 10: 1615–1623